Skeletal Dysplasia Market Expected to Reach $2,360.51 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Skeletal Dysplasia Market," The skeletal dysplasia market was valued at $1,638.1 million in 2021, and is estimated to reach $2,360.51 million by 2031, growing at a CAGR of 3.7% from 2022 to 2031.

Skeletal dysplasia is a heterogeneous group of more than 450 disorders. A wide range of diseases of the formation of the bones and cartilage are included in skeletal dysplasia. Any part of the skeleton, including abnormalities in bone size, shape, density, and short stature, might be affected due to the extremely broad range. Skeletal dysplasia caused by a disruption of bone growth in the fetal period. Some skeletal dysplasia can be detected before birth and others are identified after birth. Skeletal dysplasia is also associated with orthopedic, neurological, pulmonary, visual, auditory, cardiac, and renal issues. 

The key factors that drive the growth of the market is increase in number of cases of congenital disorders and a surge in demand for skeletal dysplasia products for treatment of various type of skeletal dysplasia. Moreover, government support programs to treat birth defects and favorable reimbursement scenario. This factor further propels the market growth during forecast period. However, poor diagnostic technologies owing to the lack of awareness is likely to hamper the growth of the optic nerve disorder treatment market during the forecast period. Conversely, increase in growth potential of emerging economies are expected to provide numerous opportunities for skeletal dysplasia market growth during the forecast period. 

Key players in the market are engaged in research and development to provide advanced medications and novel treatments for skeletal dysplasia. During the projected period, it is anticipated that the strategic collaborative research and medication designation approvals in the industry would considerably fuel market expansion and generate development potential during the forecast period. Novel drugs commercialization and the presence of pipeline products are the key reasons for the growth of the market. For instance, Denosumab is a phase III clinical trial medication being developed by Amgen Inc. for the treatment of Osteogenesis Imperfecta (OI). OI is a form of skeletal dysplasia that is often referred to as brittle bone disease that results in extremely short limbs. 

Similar to this, phase II clinical trials for recombinant human growth hormone (r-hGH) for hypochondroplasia are now being conducted by Merck KGaA. Additionally, BioMarin is working on BMN 111, which is undergoing phase III clinical trials for the treatment of pediatric achondroplasia. The skeletal abnormality known as achondroplasia hinders the transformation of cartilage into bone. Therefore, the availability of pipeline products and the launch of innovative medications are the skeletal dysplasia market trends that also contribute to the market expansion. 

By type, the morquio A syndrome segment dominated the skeletal dysplasia market size in 2021, and is expected to remain dominant throughout the forecast period, owing to the increasing incidence of morquio A syndrome.  On the other side, others segment is projected to exhibit the fastest market growth during the forecast period, owing to increase in clinical trials for of achondroplasia and osteogenesis imperfecta. 

Depending on treatment, the enzyme replacement therapy segment dominated skeletal dysplasia market share in 2021 and is projected to exhibit the fastest market growth during the forecast period, owing to increase in adoption of enzyme replacement therapy to treat the skeletal symptoms of hypophosphatasia.  

By distribution channel, the drug stores and specialty pharmacies segment dominated the skeletal dysplasia industry in 2021 and is projected to exhibit the fastest market growth during the forecast period, owing to high availability of products in settings for several types of skeletal dysplasia. In addition, growing number of specialty pharmacies and chains along with the availability of various rare disease medications drug stores and specialty pharmacies further boost the market growth. 

Region wise, North America has dominated the market in 2021 and is expected to remain dominant during the forecast period. Owing to presence of large patient population, strong presence of key players, ease of product availability, well developed healthcare infrastructure. In addition, favorable reimbursement policies in healthcare system, higher number of research and development further boost the market growth. Asia-Pacific is projected to register the highest CAGR during the forecast period. The evolving healthcare regulatory landscape and the government's emphasis on enhancing R&D capabilities for innovative product development are the key driving factors that boost the growth of the market in the region. 

Key findings of the study 

• The on the basis of type, the  morquio A syndrome segment dominated the market in 2021, and is expected to continue this trend during the forecast period. 
• On the basis of treatment, the enzyme treatment therapy segment is dominated the market in 2021, and is expected to continue this trend during the forecast period. 
• Depending on distribution channel, drug stores and specialty pharmacies segment are projected to grow at CAGR of 3.9% during the forecast period. 
• Region-wise, North-America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 4.9% during the forecast period.